SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality

Andrew Bryan; Susan L Fink; Meghan A Gattuso; Gregory Pepper; Anu Chaudhary; Mark H Wener; Chihiro Morishima; Keith R Jerome; Patrick C Mathias; Alexander L Greninger

doi:10.1093/ofid/ofaa535

SARS-CoV-2 Viral Load on Admission Is Associated With 30-Day Mortality

Open Forum Infect Dis. 2020 Nov 3;7(12):ofaa535. doi: 10.1093/ofid/ofaa535. eCollection 2020 Dec.

Authors

Andrew Bryan¹, Susan L Fink¹, Meghan A Gattuso², Gregory Pepper¹, Anu Chaudhary¹, Mark H Wener^{1

3}, Chihiro Morishima¹, Keith R Jerome^{1

4}, Patrick C Mathias^{1

5}, Alexander L Greninger^{1

4}

Affiliations

¹ Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, Washington, USA.
² Aquaelis, LLC, Seattle, Washington, USA.
³ Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
⁴ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
⁵ Department of Biomedical Informatics and Medical Education, University of Washington School of Medicine, Seattle, Washington, USA.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load on admission was associated with a significantly increased 30-day mortality (odds ratio [OR], 4.20; 95% CI, 1.62-10.86), and anti-SARS-CoV-2 nucleocapisid IgG seropositivity on admission trended toward a reduced 30-day mortality (OR, 0.43; 95% CI, 0.15-1.26). Reporting of quantitative SARS-CoV-2 viral load and serologic assays may offer prognostic clinical information.

Keywords: SARS-CoV-2; quantitative; serology; viral load.